LAURUSLABS - Fundamental Analysis: Financial Health & Valuation
Back to ListFundamental Rating: 2.7
| Stock Code | LAURUSLABS | Market Cap | 53,133 Cr. | Current Price | 984 ₹ | High / Low | 1,141 ₹ |
| Stock P/E | 66.4 | Book Value | 91.1 ₹ | Dividend Yield | 0.12 % | ROCE | 9.47 % |
| ROE | 7.75 % | Face Value | 2.00 ₹ | DMA 50 | 1,018 ₹ | DMA 200 | 915 ₹ |
| Chg in FII Hold | 0.35 % | Chg in DII Hold | 0.70 % | PAT Qtr | 175 Cr. | PAT Prev Qtr | 216 Cr. |
| RSI | 42.5 | MACD | -8.40 | Volume | 12,03,560 | Avg Vol 1Wk | 20,87,679 |
| Low price | 517 ₹ | High price | 1,141 ₹ | PEG Ratio | -2.86 | Debt to equity | 0.37 |
| 52w Index | 74.8 % | Qtr Profit Var | 206 % | EPS | 14.8 ₹ | Industry PE | 27.6 |
📊 Financial Overview
- Revenue & Profitability: PAT declined from 216 Cr. to 175 Cr. QoQ, showing earnings pressure despite a strong YoY profit variation of 206%.
- Margins & Returns: ROE at 7.75% and ROCE at 9.47% are weak compared to industry benchmarks, reflecting poor capital efficiency.
- Debt & Liquidity: Debt-to-equity ratio of 0.37 indicates moderate leverage, manageable but not ideal.
- Cash Flow: Stable but limited reinvestment capacity due to declining profitability.
💹 Valuation Metrics
- P/E Ratio: 66.4 vs Industry PE of 27.6 → Significantly overvalued.
- P/B Ratio: ~10.8 (Price 984 ₹ / Book Value 91.1 ₹) → Expensive relative to assets.
- PEG Ratio: -2.86 → Negative, reflecting poor earnings growth outlook.
- Intrinsic Value: Current price appears well above fair value zone.
🏢 Business Model & Competitive Advantage
Laurus Labs operates in pharmaceuticals, APIs, and formulations with diversification into biotech. While the industry has strong demand drivers, Laurus faces margin compression and competitive intensity. Its R&D investments provide some moat, but profitability metrics remain weak compared to peers.
📈 Entry Zone & Long-Term Guidance
Technically, RSI at 42.5 and MACD negative suggest weakness. A better entry zone would be closer to 850–900 ₹ (near 200 DMA). Long-term holding is only advisable if earnings growth revives and valuations normalize.
✅ Positive
- Moderate debt levels (0.37 D/E).
- Strong industry demand for APIs and formulations.
- Institutional investors increasing stake (FII +0.35%, DII +0.70%).
⚠️ Limitation
- High P/E and P/B ratios make valuation unattractive.
- Weak ROE and ROCE compared to industry standards.
- Profitability declining QoQ.
📉 Company Negative News
- Quarterly PAT dropped from 216 Cr. to 175 Cr.
- Margins under pressure due to rising costs.
📈 Company Positive News
- Strong YoY profit variation (206%).
- Institutional accumulation signals confidence.
🏭 Industry
Pharma sector remains structurally strong with global demand for generics and APIs. However, competition and regulatory challenges weigh on margins. Industry PE at 27.6 highlights Laurus Labs’ premium valuation.
🔎 Conclusion
Laurus Labs is fundamentally overvalued with weak return ratios and declining profitability. While the business model has long-term potential, current valuations do not justify entry. A cautious approach is recommended, with accumulation only near 850–900 ₹ levels for long-term investors.